Literature DB >> 1376110

Human platelet glycoprotein IIIb binds to thrombospondin fragments bearing the C-terminal region, and/or the type I repeats (CSVTCG motif), but not to the N-terminal heparin-binding region.

B Catimel1, L Leung, H el Ghissasi, N Mercier, J McGregor.   

Abstract

Major blood membrane platelet glycoprotein IIIb (GPIIIb), also termed GPIV or CD365, has been identified as a receptor for thrombospondin (TSP), collagen and Plasmodium falciparum-infected erythrocytes. The aim of the present study was to identify region(s) of TSP involved in binding of GPIIIb. Proteolytic fragments of TSP (M(r) 140 kDa, 120-18 kDa and 27 kDa on SDS/PAGE under reducing conditions) were purified by f.p.l.c. and identified by N-terminal gas-phase sequencing, e.l.i.s.a. and Western blots using monoclonal antibodies directed against defined domains of TSP. The 140 kDa and 120-18 kDa fragments (C-terminal region), but not the 27 kDa fragment (N-terminal region), were shown to bind to GPIIIb by using e.l.i.s.a. and affinity-chromatography systems. TSP binding to a GPIIIb-affinity column was Ca(2+)-dependent and reduced by 45% in the presence of EDTA. Moreover, TSP was only partially eluted with EDTA from a Ca(2+)-equilibrated GPIIIb column. A fragment of 68 kDa, obtained by further digestion of the 140 kDa fragment, bound to the GPIIIb-Sepharose affinity column. This fragment, or stalk-like region, bears the TSP type I repeats that show sequence similarity to regions on properdin, Plasmodium falciparum proteins and antistasin. Peptides (CSVTCG or SVTCGGGV) representing these repeats bound isolated GPIIIb in a Ca(2+)-independent way, but did not completely inhibit the GPIIIb and TSP interaction. These studies indicate that GPIIIb binds to the TSP via the C-terminal region and/or the CSVTCG motif, but not to the N-terminal region. Interaction between GPIIIb and the TSP C-terminal region or the CSVTCG motif is respectively Ca(2+)-dependent and -independent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376110      PMCID: PMC1132721          DOI: 10.1042/bj2840231

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

1.  PAS IV, an integral membrane protein of mammary epithelial cells, is related to platelet and endothelial cell CD36 (GP IV).

Authors:  D E Greenwalt; K W Watt; O Y So; N Jiwani
Journal:  Biochemistry       Date:  1990-07-31       Impact factor: 3.162

2.  Effects of thrombin, chymotrypsin and aggregated gamma-globulins on the proteins of the human platelet membrane.

Authors:  B Podolsak
Journal:  Thromb Haemost       Date:  1977-06-30       Impact factor: 5.249

3.  Thrombospondin-induced adhesion of human platelets.

Authors:  G P Tuszynski; M A Kowalska
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

4.  Epithelial membrane glycoprotein PAS-IV is related to platelet glycoprotein IIIb binding to thrombospondin but not to malaria-infected erythrocytes.

Authors:  B Catimel; J L McGregor; T Hasler; D E Greenwalt; R J Howard; L L Leung
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

5.  Cell-adhesive motif in region II of malarial circumsporozoite protein.

Authors:  K A Rich; F W George; J L Law; W J Martin
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

6.  Identification of the platelet-specific alloantigen, Naka, on platelet membrane glycoprotein IV.

Authors:  Y Tomiyama; H Take; H Ikeda; T Mitani; T Furubayashi; H Mizutani; N Yamamoto; N N Tandon; S Sekiguchi; G A Jamieson
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

7.  Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders.

Authors:  R B Bolin; T Okumura; G A Jamieson
Journal:  Am J Hematol       Date:  1977       Impact factor: 10.047

8.  Properdin binds to sulfatide [Gal(3-SO4)beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates.

Authors:  G D Holt; M K Pangburn; V Ginsburg
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

9.  The endogenous lectin of human platelets is an alpha-granule component.

Authors:  T K Gartner; J M Gerrard; J G White; D C Williams
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

10.  The properdin-like type I repeats of human thrombospondin contain a cell attachment site.

Authors:  C A Prater; J Plotkin; D Jaye; W A Frazier
Journal:  J Cell Biol       Date:  1991-03       Impact factor: 10.539

View more
  6 in total

1.  Plasmodium yoelii sporozoites infect CD36-deficient mice.

Authors:  Photini Sinnis; Maria Febbraio
Journal:  Exp Parasitol       Date:  2002-01       Impact factor: 2.011

2.  Cell adhesion to a motif shared by the malaria circumsporozoite protein and thrombospondin is mediated by its glycosaminoglycan-binding region and not by CSVTCG.

Authors:  S M Gantt; P Clavijo; X Bai; J D Esko; P Sinnis
Journal:  J Biol Chem       Date:  1997-08-01       Impact factor: 5.157

3.  Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva.

Authors:  R Crombie; R L Silverstein; C MacLow; S F Pearce; R L Nachman; J Laurence
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

4.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

5.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity.

Authors:  S S Tolsma; O V Volpert; D J Good; W A Frazier; P J Polverini; N Bouck
Journal:  J Cell Biol       Date:  1993-07       Impact factor: 10.539

6.  Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

Authors:  H Boukerche; O Berthier-Vergnes; E Tabone; M Bailly; J F Doré; J L McGregor
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.